SCHEMBL3484861

SCHEMBL3484861

COC(=O)C(C)NC(=O)c1ncc(-c2ccc3c(c2)OCCO3)cc1O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.43
CHEK2 O96017 1/20 0.43
ALOX5 P09917 1/20 0.43
EGLN1 Q9GZT9 9/20 0.42
VEGFA P15692 5/20 0.42
FLT1 P17948 5/20 0.42
EGLN3 Q9H6Z9 3/20 0.42
ALDH1A1 P00352 4/20 0.40
MAPK1 P28482 1/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39
ALOX12 P18054 1/20 0.39
HTT P42858 1/20 0.39
CLK1 P49759 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3484492 0.91 ALDH1A1 (0.46) CHEK1CHEK2ALOX5EGLN1VEGFA
SCHEMBL3485259 0.91 CHEK2 (0.47) CHEK1CHEK2ALOX5EGLN1VEGFA
SCHEMBL3485031 0.89 TSHR (0.49) CHEK1CHEK2ALOX5EGLN1VEGFA
SCHEMBL3484718 0.88 ALOX5 (0.43) CHEK1CHEK2ALOX5EGLN1VEGFA
SCHEMBL3485346 0.87 ALOX5 (0.42) CHEK1CHEK2ALOX5EGLN1VEGFA
SCHEMBL3485422 0.81 EGLN1 (0.44) CHEK1CHEK2ALOX5EGLN1VEGFA
SCHEMBL14331216 0.80 EGLN1 (0.57) EGLN1VEGFAFLT1EGLN3
SCHEMBL3485876 0.80 EGLN1 (0.67) EGLN1VEGFAFLT1EGLN3
SCHEMBL3485365 0.78 EGLN1 (0.58) EGLN1VEGFAFLT1EGLN3
SCHEMBL3484922 0.78 EGLN1 (0.44) CHEK1CHEK2ALOX5EGLN1VEGFA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160009648-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE KREOS CAPITAL VII (UK) LIMITED (GB) 2016-01-14 US claimed
US-8343952-B2 Prolyl hydroxylase inhibitors and methods of use AKEBIA THERAPEUTICS INC. (US) 2013-01-01 US claimed
US-20100331303-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE AKEBIA THERAPEUTICS, INC. 2010-12-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009648-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE HIF1AN, EGLN3, HIF1A CHEK1 3883/4885CHEK2 4502/4885ALOX5 624/4885
US-20100331303-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE HIF1AN, EGLN3, HIF1A CHEK1 3883/4885CHEK2 4502/4885ALOX5 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.